UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 239

Sortiert nach

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

Bone marrow transplantation (Basingstoke), 2021-05, Vol.56 (5), p.1180-1189

2021

Volltextzugriff (PDF)

Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited

Cancer treatment reviews, 2010-11, Vol.36 (7), p.528-538

2010

Volltextzugriff (PDF)

Comparison of myeloablative and reduced intensity conditioning regimens in haploidentical peripheral blood stem cell transplantation

Bone marrow transplantation (Basingstoke), 2021-03, Vol.56 (3), p.741-744

2021

Volltextzugriff (PDF)

Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?

Bone marrow transplantation (Basingstoke), 2020-08, Vol.55 (8), p.1655-1657

2020

Volltextzugriff (PDF)

Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis

Annals of hematology, 2021-04, Vol.100 (4), p.969-978

2021

Volltextzugriff (PDF)

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients

Oncoimmunology, 2020-01, Vol.9 (1), p.1773201-1773201

2020

Volltextzugriff (PDF)

Absolute lymphocyte count on the first day of thymoglobulin predicts relapse-free survival in matched unrelated peripheral blood stem cell transplantation

Leukemia & lymphoma, 2020-11, Vol.61 (13), p.3137-3145

2020

Volltextzugriff (PDF)

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML

Blood, 2018-11, Vol.132 (Supplement 1), p.662-662

2018

Volltextzugriff (PDF)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002194

2021

Volltextzugriff (PDF)

Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation

American journal of hematology, 2016-09, Vol.91 (9), p.E341-E347

2016

Volltextzugriff (PDF)

Rapid and sustained response to Chimeric Antigen Receptor T cell therapy in double hit diffuse large B cell lymphoma

American journal of hematology, 2020-03, Vol.95 (3), p.333-334

2020

Volltextzugriff (PDF)

PB2346: ZUMA‐24: A PHASE 2, OPEN‐LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING

HemaSphere, 2023-08, Vol.7 (S3), p.e50042ff-n/a

2023

Volltextzugriff (PDF)

S202: CARTITUDE‐1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e6102468-n/a

2023

Volltextzugriff (PDF)

Malignant Cause of Abdominal Pain in Leukemia: Spontaneous Splenic Rupture

The American journal of the medical sciences, 2015-02, Vol.349 (2), p.189-190

2015

Volltextzugriff (PDF)

Epidemiology and Predictors of Readmission in CAR T-Cell Therapy Recipients

Blood, 2021-11, Vol.138 (Supplement 1), p.3010-3010

2021

Volltextzugriff (PDF)

Mortality in COVID-19 hospitalizations with underlying hematologic malignancies in the United States

Hematological oncology, 2023-10, Vol.41 (4), p.781-783

2023

Volltextzugriff (PDF)

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Journal of clinical oncology, 2020-09, Vol.38 (27), p.3119-3128

2020

Volltextzugriff (PDF)

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

The Lancet (British edition), 2021-07, Vol.398 (10297), p.314-324

2021

Volltextzugriff (PDF)

Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.108.e1-108.e7

2023

Volltextzugriff (PDF)

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood, 2020-06, Vol.135 (23), p.2106-2109

2020

Volltextzugriff (PDF)

Haploidentical vs. mismatched unrelated donor transplants with posttransplant cyclophosphamide-based GVHD prophylaxis

Bone marrow transplantation (Basingstoke), 2024-08, Vol.59 (8), p.1196-1198

2024

Volltextzugriff (PDF)

HLA-Haploidentical Vs Mismatched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis for AML and MDS: Is There a Winner?

Blood, 2022-11, Vol.140 (Supplement 1), p.694-695

2022

Volltextzugriff (PDF)

1 – 25 von 239

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(207)
Mit Volltextzugriff
(220)

Publikationsform

Sprache

Englisch
(239)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(63)
Humans
(53)
Hematology
(46)
Oncology
(33)
Middle Aged
(31)
Adult
(28)
Male
(28)
Female
(27)
Aged
(26)
Transplantation
(23)
Immunology
(21)
Stem Cell Transplantation
(20)
Hematology, Oncology And Palliative Medicine
(17)
Retrospective Studies
(17)
Hematopoietic Stem Cell Transplantation
(15)
Multiple Myeloma
(12)
Transplantation, Autologous
(12)
Stem Cells
(11)
Graft Vs Host Disease - Prevention & Control
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited

Comparison of myeloablative and reduced intensity conditioning regimens in haploidentical peripheral blood stem cell transplantation

Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?

Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients

Absolute lymphocyte count on the first day of thymoglobulin predicts relapse-free survival in matched unrelated peripheral blood stem cell transplantation

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation

Rapid and sustained response to Chimeric Antigen Receptor T cell therapy in double hit diffuse large B cell lymphoma

PB2346: ZUMA‐24: A PHASE 2, OPEN‐LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING

S202: CARTITUDE‐1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Malignant Cause of Abdominal Pain in Leukemia: Spontaneous Splenic Rupture

Epidemiology and Predictors of Readmission in CAR T-Cell Therapy Recipients

Mortality in COVID-19 hospitalizations with underlying hematologic malignancies in the United States

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Haploidentical vs. mismatched unrelated donor transplants with posttransplant cyclophosphamide-based GVHD prophylaxis

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

HLA-Haploidentical Vs Mismatched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis for AML and MDS: Is There a Winner?

Suchergebnisse filtern